On July 13, 2026, the Supreme People's Court of China upheld EDAN Diagnostics' medical device patent in case (2022) Zui Gao Fa Zhi Xing Zhong No. 255, rejecting an invalidation challenge that argued the invention was "completed in China" and therefore required a pre-filing security review that never happened. The ruling matters because it sets a concrete evidentiary framework for one of the most ambiguous provisions in Chinese patent law: Article 19. Any company with cross-border R&D that files patents in multiple jurisdictions needs to understand what this decision requires.

Foreign companies with R&D operations in China have been navigating a gray zone for years. The law says you need CNIPA security clearance before filing abroad if your invention was "completed in China." But what counts as "completed"? And who has to prove what? The EDAN ruling answers both questions with more precision than any prior decision.

What the Case Was Actually About

Guangzhou WanXX Biotechnology filed an invalidation petition against EDAN Diagnostics' Chinese patent CN201310322059.8, which covers an in-vitro diagnostic device and system. The patent claimed priority from a December 2012 US filing and was granted in China in October 2015.

WanXX's argument was straightforward: the R&D was allegedly funded by a Guangdong provincial government project executed by a Shenzhen-based EDAN affiliate. If true, the invention was "completed in China" and EDAN's direct US filing without CNIPA security review violated Article 19 of the Patent Law. Under Article 19(4), the Chinese patent should be invalidated.

The Patent Law says this in language that looks simple but has proven difficult to apply:

Article 19(1): Any entity or individual that intends to file a foreign patent application for an invention or utility model completed in China shall first submit it to the patent administrative department of the State Council for confidentiality examination.Article 8 of the Implementation Regulations: "Completed in China" means the substantive content of the technical solution was completed within China."Substantive content" is the operative term. Not the full patent specification. Not where the funding came from. Not where commercialization happened. The technical contribution itself.

The Supreme People's Court's Intellectual Property Tribunal agreed with CNIPA and the Beijing IP Court: EDAN's evidence showed the substantive content was developed in the United States.

Three Questions the Court Answered

The ruling resolves three questions that have dogged foreign filing security review disputes.

First, what is "substantive content"? The court rejected the argument that you should look at the full independent claim. Instead, it compared the invention against the closest prior art. The first-named inventor testified that the three inventive contributions over Abbott's existing point-of-care testing device were: (a) separating the test card from the reagent pack instead of using a combined single-use unit; (b) eliminating internal fluid pathways inside the instrument; and (c) replacing manual loading with automatic sample loading. The court accepted this framing. Features recited in dependent claims that amounted to routine engineering refinement were not treated as part of the "substantive content."

Second, what evidence proves where the work happened? The court relied on contemporaneous emails exchanged among the three inventors between January and June 2010, cross-checking their content for internal consistency. These emails discussed test-card fluid channel design, T-connector specifications, heater model numbers, and the vacuum pump mechanism for automated loading. The court also reviewed passport records showing that none of the inventors had substantial presence in China during this period: one was there for 58 days, a second was never in China, and no evidence placed the third inventor in China before the relevant date.

Third, who bears the burden of proof? The petitioner must establish, with "high probability," that the substantive content was completed in China. Inventor nationality, applicant address, and government funding source are not enough on their own. CNIPA's prior practice had already rejected arguments based solely on inventor citizenship or company registration address, but this SPC ruling crystallizes the standard across all levels of review.

The petitioner challenged the authenticity of some emails, arguing they could have been edited when retrieved years later. The court found the emails credible based on internal coherence, chronological logic, and corroboration with unchallenged correspondence.

What Foreign Companies Should Do Now

The ruling is useful because it tells you what to document before you have a dispute.

If your company runs R&D across multiple countries and files patents in multiple jurisdictions, you need to build a defensible record of where the inventive work happened. The court's hierarchy of evidence is instructive: contemporaneous technical communications ranked higher than post-hoc declarations. Internal consistency across documents mattered more than the volume of material submitted.

Document the inventive timeline. Keep dated design files, version-controlled schematics, and lab notebooks that tie specific inventive contributions to specific dates and locations. The court relied on emails that showed technical problems being solved in real time. Generic meeting notes or summary reports won't carry the same weight.

Map inventor contributions to locations. Your patent filings should accurately list inventors. For each person, maintain records of where they were during the period when key inventive steps took place. This doesn't mean tracking every employee's movements daily. But if the three people who solved the core technical problem were all in Boston in June 2010, you should be able to prove it.

Assess security review obligations separately for each filing. Do not assume that because your parent company is incorporated abroad, the security review requirement does not apply. CNIPA has been explicit on this point: the test is where the substantive technical work happened, not where the applicant entity is registered. A US company with a Shanghai lab doing genuine inventive work needs the security review before filing in the US. A Chinese company whose inventors did the real work in San Diego does not.

Don't try to fix this retroactively. CNIPA's own Q&A states there is no remedial procedure. If you file abroad first and later realize you should have requested a security review, submitting the request after the fact does not cure the violation.

Check before launching invalidation challenges. For companies contemplating an invalidation attack based on Article 19, the EDAN ruling raises the evidentiary bar. You need more than a government grant document and a Chinese inventor's name. You need contemporaneous technical evidence tying the inventive content to Chinese territory. Fishing expeditions based on the petitioner's burden-shifting argument were rejected by this court.

The Bigger Picture

This ruling arrives at a moment when China's patent system is tightening across multiple fronts. The 2023 revision to the Implementation Regulations explicitly added Article 19(1) violations as a ground for invalidation under Article 69. The Patent Examination Guidelines were revised effective January 2026. And CNIPA has been more willing to invalidate patents on procedural grounds in the past two years than at any point in the prior decade.

The message to foreign patent holders is clear: procedural compliance matters. A valid invention can lose protection if the filing sequence was wrong.

The security review requirement itself is not unique to China. The US has its foreign filing license system under 35 USC 184. India requires permission from the Indian Patent Office. But China's regime is distinctive in two respects: it applies to any entity regardless of nationality, and it uses invalidation as the enforcement mechanism rather than criminal penalties or fines. Losing a granted patent through post-grant invalidation is arguably a more painful consequence for commercial actors than a regulatory fine.

For cross-border patent strategy, the practical implication is to treat the security review assessment as a mandatory pre-filing gate. Before routing a new application to the USPTO or EPO, ask: did any of the inventive contribution happen on Chinese soil? If the answer is yes, file the security review request with CNIPA first. The process is administrative and typically resolves within four to six months under the statutory timeline.